Deborah Morosini - 15 Dec 2021 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role
EVP, Chief of Clinical Affairs
Signature
/s/ Krishna Vaddi, Attorney-in-Fact
Issuer symbol
PRLD
Transactions as of
15 Dec 2021
Net transactions value
-$37,368
Form type
4
Filing time
17 Dec 2021, 16:20:12 UTC
Previous filing
18 Nov 2021
Next filing
17 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRLD Common Stock Options Exercise $5,700 +3,016 +679% $1.89 3,460 15 Dec 2021 Direct
transaction PRLD Common Stock Options Exercise $330,695 +25,735 +744% $12.85 29,195 15 Dec 2021 Direct
transaction PRLD Common Stock Sale $373,763 -28,751 -98% $13.00 444 15 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PRLD Employee Stock Option (right to buy) Options Exercise $0 -3,016 -70% $0.000000 1,307 15 Dec 2021 Common Stock 3,016 $1.89 Direct F2
transaction PRLD Employee Stock Option (right to buy) Options Exercise $0 -24,853 -25% $0.000000 74,575 15 Dec 2021 Common Stock 24,853 $12.85 Direct F3
transaction PRLD Employee Stock Option (right to buy) Options Exercise $0 -882 -0.45% $0.000000 195,163 15 Dec 2021 Common Stock 882 $12.85 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The stock option is fully vested.
F3 The stock option vests as to 25% of the total shares monthly beginning on September 24, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
F4 The stock option vests as to 25% of the total shares monthly beginning on July 27, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.